heptatriaconta-6,9,28,31-tetraen-19-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: heptatriaconta-6,9,28,31-tetraen-19-ol
• 英文别名: dilinoleyl methanol；Heptatriaconta-6,9,28,31-tetraen-19-ol
• 化学式: C₃₇H₆₈O
• 分子量: 528.946
• InChiKey: MXYDYSQZZPJVJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.1
• 重原子数：
  38
• 可旋转键数：
  30
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  heptatriaconta-6,9,28,31-tetraen-19-ol 在 吡啶 、 三乙胺 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 52.08h， 生成 (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl (3-(diethylamino)propyl)(methyl)carbamate
  参考文献：
  名称：

  [EN] NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF
  [FR] NOUVEAUX LIPIDES CATIONIQUES ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  公开号：

  WO2011141705A8
• 作为产物：
  描述：

  methanesulfonic acid octadeca-9,12-dienyl ester 在 乙醚溴化镁 、 magnesium 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 4.67h， 生成 heptatriaconta-6,9,28,31-tetraen-19-ol
  参考文献：
  名称：

  [EN] NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF
  [FR] NOUVEAUX LIPIDES CATIONIQUES ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  公开号：

  WO2011141705A8

文献信息

• [EN] NUCLEIC ACID CHEMICAL MODIFICATIONS<br/>[FR] MODIFICATIONS CHIMIQUES D'ACIDE NUCLÉIQUE
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2010101951A1

  公开（公告）日：2010-09-10

  he present invention provides nucleosides of formula (1) and oligonucleotides comprising at least on nucleoside of formula (2): Another aspect of the invention relates to a method of inhibiting the expression of a gene in cell, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

  本发明提供了式（1）的核苷和包含至少一种式（2）核苷的寡核苷酸；发明的另一个方面涉及一种抑制细胞中基因表达的方法，该方法包括（a）将本发明的寡核苷酸与细胞接触；和（b）维持步骤（a）中的细胞足够长的时间以获得目标基因mRNA的降解。
• LIPIDOSOME PREPARATION, PREPARATION METHOD AND APPLICATION THEREOF
  申请人：BIOMICS BIOTECHNOLOGIES CO., LTD.

  公开号：US20150272886A1

  公开（公告）日：2015-10-01

  The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.

  本发明公开了一种脂质体配方，其制备方法以及在治疗由异常基因表达引起的疾病中的应用。该脂质体配方包括互补的阳离子脂质对、磷脂和长循环脂质。制备该脂质体配方的方法包括：将互补的阳离子脂质对与磷脂和长循环脂质混合以生成预形成的囊泡；然后将预形成的囊泡与核酸溶液混合以生成脂质体-核酸配方。本发明提供的这种脂质体配方易于制备；在治疗由异常基因表达引起的疾病中，可以使用该脂质体配方来输送体内治疗剂，包括核酸。
• [EN] NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS D'ACIDE NUCLÉIQUE-POLYPEPTIDE ET UTILISATIONS DE CELLES-CI
  申请人：AVIDITY BIOSCIENCES INC

  公开号：WO2020247782A1

  公开（公告）日：2020-12-10

  Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

  本文披露了包括与修饰的多核苷酸分子和聚合物结合的结合基团的组合物和药物配方。本文还描述了利用包括结合基团与多核苷酸分子和聚合物结合的组合物或药物配方治疗癌症的方法。
• [EN] IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS<br/>[FR] LIPIDES AMINÉS AMÉLIORÉS ET PROCÉDÉS D'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：TEKMIRA PHARMACEUTICALS CORP

  公开号：WO2010042877A1

  公开（公告）日：2010-04-15

  The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

  本发明提供了用于将治疗剂传递给细胞的优越组合物和方法。具体来说，这些包括新型脂质和核酸-脂质颗粒，能够有效地封装核酸并有效地将封装的核酸传递给体内的细胞。本发明的组合物具有高度的效力，因此可以以相对较低的剂量有效地降低特定靶蛋白的表达。此外，本发明的组合物和方法与先前在艺术领域中已知的组合物和方法相比，毒性更低，并提供更大的治疗指数。
• [EN] AMINO LIPID BASED IMPROVED LIPID FORMULATION<br/>[FR] FORMULATION LIPIDIQUE AMÉLIORÉE À BASE D'AMINO LIPIDE
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2009132131A1

  公开（公告）日：2009-10-29

  The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic aicd to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. Formulae (I), (II), (III), (IV).

  本发明提供了将治疗剂传递给细胞的组合物和方法。特别是，这些包括新型脂质和核酸-脂质颗粒，它们能够高效地封装核酸并将封装的核酸有效地传递到体内细胞中。本发明的组合物非常强效，因此可以在相对较低的剂量下有效地降低特定靶蛋白的表达。此外，与先前已知的技术中的组合物和方法相比，本发明的组合物和方法毒性更低，疗效指数更高。公式（I）、（II）、（III）、（IV）。